Early-stage life sciences enterprises are set to benefit from a unique new collaboration between Birmingham’s Precision Health Technologies Accelerator (PHTA) and Oxford Science Enterprises (OSE).
The partnership will focus on helping high-growth health technology and life sciences companies to scale, primarily through access to high-quality lab and innovation space, while also catalysing cross-regional collaboration between academics and enterprises.
PHTA is the University of Birmingham (UoB)’s flagship life sciences research accelerator, where entrepreneurs, start-ups and scale-ups…
Stevenage, 18th May, 2023 – Kadans Science Partner (Kadans), the European leader in developing science and technology real estate, today announces the launch of Sycamore House, a new laboratory and office facility for innovative, high-growth life science companies and Kadans’ first completed development in the UK. By adding Sycamore House to the portfolio, Kadans is furthering its goal to create one strong knowledge-sharing ecosystem of science parks across Europe. Their portfolio now comprises over 45 buildings and numerous projects under development in the Netherlands, the United Kingdom,…
Pharmanovia’s leading medicine brands to be combined with Closed Loop Medicine’s technology to provide dose optimized personalized therapies
Global (ex-US) co-development and commercialization partnership to initially focus on next-generation drug + software product solutions for the treatment of hypertension
London and Basildon, UK, 17 May 2023: Closed Loop Medicine Ltd, a leading TechBio company, developing combination prescription drug plus software therapy products that enable personalized dose optimization, and Pharmanovia, a global pharmaceutical company that…
AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.
Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cells for treatment of leukemia and lymphoma. Consequently, there is now rapid growth in research on the therapeutic uses of CAR-T cells.
Increasingly CAR-T cell therapies are being employed as a strategy to redirect a patient’s T-cells to target and destroy specific tumor cells. Researchers have…
Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort
Cambridge, UK, 16th May 2023: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to officially welcome six new ventures to Accelerate@Babraham 2023.
Chosen via a rigorous selection process which culminated in short-listed companies being interviewed by representatives of the Babraham Research Campus executive team and all the programme’s strategic partners,…
Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has launched a new in vitro model of the blood brain barrier (BBB) for research into neurodegenerative diseases.
Developed and prepared in-house, INNOBEX™ is an in vitro model comprised of three primary cell types: endothelial cells (HBMVEC), pericytes and astrocytes. The model can be used with assays including TEER (transendothelial electrical resistance) and FITC Dextran to assess the permeability of the BBB and to determine if a drug is acting on the cells of the BBB to affect the permeability. Other assay…
London and Oxford, UK, 15 May 2023 – Self funded, not-for-profit medical research organisation LifeArc and techbio company PrecisionLife announce a strategic R&D collaboration to accelerate the discovery and development of targeted treatments for motor neuron disease (MND) - also known as amyotrophic lateral sclerosis (ALS), and Lou Gehrig's disease. The collaboration will accelerate pioneering findings by PrecisionLife working with the Motor Neurone Disease Association and leading clinicians at King’s College London and the University of Sheffield to analyse genotyped patient data…
First delivery and use of DNA manufactured using Evonetix's unique thermally controlled synthesis technology
Key milestone in the development of Evonetix's desktop DNA synthesis platform
Cambridge, UK, 10 May 2023– EVONETIX LTD (‘Evonetix’), the company bringing semiconductor technology to DNA synthesis, today announced that DNA synthesized using its unique semiconductor chip technology was delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. This milestone marks the start of the next stage of development of the Company as…
The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years.
Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through out-licencing, partnerships or global biopharma buy-outs.
To hear more about the findings, please read the latest report by the Deloitte Life Sciences Catalyst team.
https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-scienc…
Source LDPath’s outstanding digital integration with East Kent Hospital NHS Foundation Trust (EKHUFT) pathology department has been selected as the winner of the “Best Hospital Technology Implementation” award in the 7th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough.
The integration was finalised in June 2022 to digitise the pathology department of the Trust, which has greatly reduced their cancer diagnostic reporting times. The success seen in this collaboration between Source LDPath and EKHUFT has been recognised as a clinical success for improving overall…